文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

血浆ACE2与死亡或心血管代谢疾病风险:一项病例-队列分析

Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis.
PubMed 文献 · Lancet · 2020-01-01
一句话结论在PURE研究中,血浆ACE2浓度每升高1个标准差,总死亡风险HR 1.35,心血管与非心血管死亡风险相似升高。

该研究基于前瞻性城乡流行病学(PURE)研究,在来自五大洲14个国家的10753名参与者中开展病例-队列分析,检测血浆ACE2浓度并分析其决定因素及与心血管事件的关联。结果显示,血浆ACE2每升高1个标准差,总死亡风险HR 1.35(95%CI 1.29-1.43),心血管与非心血管死亡风险相似升高; incident心力衰竭HR 1.27(1.10-1.46)、心肌梗死HR 1.23(1.13-1.33)、卒中HR 1.21(1.10-1.32)、糖尿病HR 1.44(1.36-1.52)。这些关联独立于年龄、性别、 ancestry和传统心脏危险因素;除incident心力衰竭外,调整BNP后ACE2与包括死亡在内的临床终点的独立关联仍然稳健。ACE2浓度的最强决定因素为性别、 geographic ancestry和BMI;与临床危险因素相比,ACE2是死亡的最高排名预测因子,并在心力衰竭、卒中和心肌梗死预测上超越若干危险因素。

要点

  • 在PURE研究10753名参与者中,血浆ACE2每升高1个标准差,总死亡风险HR 1.35(95%CI 1.29-1.43),心血管与非心血管死亡风险相似升高。
  • 血浆ACE2每升高1个标准差,incident心力衰竭HR 1.27(1.10-1.46)、心肌梗死HR 1.23(1.13-1.33)、卒中HR 1.21(1.10-1.32)、糖尿病HR 1.44(1.36-1.52)。
  • 上述关联独立于年龄、性别、ancestry和传统心脏危险因素;除incident心力衰竭外,调整BNP后ACE2与包括死亡在内的临床终点的独立关联仍然稳健。
  • ACE2浓度的最强决定因素为性别、 geographic ancestry和BMI;与吸烟、糖尿病、血压、血脂和BMI等临床危险因素相比,ACE2是死亡的最高排名预测因子,并在心力衰竭、卒中和心肌梗死预测上超越若干危险因素。

适用人群与场景

  • PURE前瞻性研究的参与者,来自五大洲14个国家(非洲、亚洲、欧洲、北美和南美),共纳入10753名参与者进行病例-队列分析。

研究设计与关键结果

  • 研究类型:在PURE前瞻性研究内开展的病例-队列分析,纳入10753名参与者,来自14个国家。
  • 主要终点:血浆ACE2每升高1个标准差,总死亡风险HR 1.35(95%CI 1.29-1.43),心血管与非心血管死亡风险相似升高。
  • 关键次要终点:incident心力衰竭HR 1.27(95%CI 1.10-1.46)、心肌梗死HR 1.23(95%CI 1.13-1.33)、卒中HR 1.21(95%CI 1.10-1.32)、糖尿病HR 1.44(95%CI 1.36-1.52),均为血浆ACE2每升高1个标准差。
  • 上述关联独立于年龄、性别、ancestry和传统心脏危险因素;除incident心力衰竭外,调整BNP后ACE2与包括死亡在内的临床终点的独立关联仍然稳健。
  • ACE2浓度的最强决定因素为性别、 geographic ancestry和BMI;与临床危险因素(吸烟、糖尿病、血压、血脂和BMI)相比,ACE2是死亡的最高排名预测因子,并在心力衰竭、卒中和心肌梗死预测上超越若干危险因素。

证据类型、等级与局限

  • 证据类型:前瞻性研究(PURE)内的病例-队列分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论:血浆ACE2浓度升高与重大心血管事件风险增加相关;原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Angiotensin-converting enzyme 2 (ACE2) is an endogenous counter-regulator of the renin-angiotensin hormonal cascade. We assessed whether plasma ACE2 concentrations were associated with greater risk of death or cardiovascular disease events.

METHODS: We used data from the Prospective Urban Rural Epidemiology (PURE) prospective study to conduct a case-cohort analysis within a subset of PURE participants (from 14 countries across five continents: Africa, Asia, Europe, North America, and South America). We measured plasma concentrations of ACE2 and assessed potential determinants of plasma ACE2 levels as well as the association of ACE2 with cardiovascular events.

FINDINGS: We included 10 753 PURE participants in our study. Increased concentration of plasma ACE2 was associated with increased risk of total deaths (hazard ratio [HR] 1·35 per 1 SD increase [95% CI 1·29-1·43]) with similar increases in cardiovascular and non-cardiovascular deaths. Plasma ACE2 concentration was also associated with higher risk of incident heart failure (HR 1·27 per 1 SD increase [1·10-1·46]), myocardial infarction (HR 1·23 per 1 SD increase [1·13-1·33]), stroke (HR 1·21 per 1 SD increase [1·10-1·32]) and diabetes (HR 1·44 per 1 SD increase [1·36-1·52]). These findings were independent of age, sex, ancestry, and traditional cardiac risk factors. With the exception of incident heart failure events, the independent relationship of ACE2 with the clinical endpoints, including death, remained robust after adjustment for BNP. The highest-ranked determinants of ACE2 concentrations were sex, geographic ancestry, and body-mass index (BMI). When compared with clinical risk factors (smoking, diabetes, blood pressure, lipids, and BMI), ACE2 was the highest ranked predictor of death, and superseded several risk factors as a predictor of heart failure, stroke, and myocardial infarction.

INTERPRETATION: Increased plasma ACE2 concentration was associated with increased risk of major cardiovascular events in a global study.

FUNDING: Canadian Institute of Health Research, Heart & Stroke Foundation of Canada, and Bayer.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Narula S, Yusuf S, Chong M, et al. Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. Lancet. 2020. PMID: 33010842. doi:10.1016/S0140-6736(20)31964-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。